glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1
Pay in 4 interest-free payments of $5.37 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1](https://www.researchgate.net/publication/407114666/figure/fig1/AS:11431282192134370@1781583549647/Abbreviations-GLP-1-RA-glucagon-like-peptide-1-receptor-agonist-n-number-of.png)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1](https://images.squarespace-cdn.com/content/v1/535bcb2fe4b05fe61b320c51/ff763443-50b9-464e-8c57-8a57698eb810/image7.png)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1](https://evidence.nejm.org/cms/10.1056/EVIDoa2500173/asset/d46fac1d-6511-43aa-8e5a-a16bb0443306/assets/images/large/evidoa2500173_t1.jpg)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1](https://www.aasld.org/sites/default/files/2023-05/figure%201.jpeg)
![glp 1 nejm In an earlier analysis of the SURMOUNT-1 trial, tirzepatide (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide -1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Abbreviations: GLP-1 RA, glucagon-like peptide-1](https://www.nejm.org/cms/asset/ce1e2adf-f3d9-473d-88ac-ae012685c50e/nejmoa2028198_f1.jpg)






















